封面
市場調查報告書
商品編碼
922002

全球血脂異常症治療市場:成長,趨勢,及預測

Lipid Disorder Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 109 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

本報告提供全球血脂異常症治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各適應症·流通管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 各種文明病的盛行率增加
    • 抽煙和酒精消費的增加
  • 市場阻礙因素
    • 治療的副作用
  • 波特的五力分析

第5章 市場區隔

  • 各適應症
    • 高膽固醇症
    • β脂蛋白異常
    • 遺傳性複合高血脂症
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Pfizer, Inc
    • Novartis AG
    • Astrazeneca Plc
    • Merck & Co.
    • Emcure Pharmaceuticals Ltd.
    • Ranbaxy Laboratories Ltd.
    • Teva Pharmaceuticals
    • Mylan Pharmaceuticals, Inc.
    • Kowa Pharmaceuticals America, Inc.(興和株式會社)
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceuticals Industries Ltd.

第7章 市場機會及今後趨勢

簡介目錄
Product Code: 67742

The major factors attributing to the growth of the lipid disorder treatment market are the growing prevalence of lifestyle diseases like obesity and increasing smoking and alcohol consumption. Lifestyle diseases are conditions associated with the way people live. They include atherosclerosis, heart disease, stroke, obesity, and type 2 diabetes. As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese, However, in 2018, 40 million children under the age of 5 were overweight or obese.

Furthermore, the increasing growth of familial combined hyperlipidemia incidence rate also plays a major role in the growth of the market. However, the side effects of the medication involved in the treatment are the restraint to the growth of the market.

Key Market Trends

Familial Combined Hyperlipidemia Incidence Rate is Expected to Show a High Growth

Familial combined hyperlipidemia is the most common congenital disorder that increases blood fats. It causes high cholesterol and high blood triglycerides which can cause early heart attacks. The rate of incidence of this disease is high in adults, and the treatment market for the disease is profitable for the key players involved in the manufacturing of the drugs. As this condition is common, the drugs for this disease have maximum sales and generates maximum revenue.

Statins are the class of drugs that are used to treat familial combined hyperlipidemia, the same is used to treat related conditions like obesity. Therefore as the incidence of obesity increases the market growth rate of this segment also increases.

As per the National Organization for Rare Disorders(NORD), 1 in 220 people have familial combined hyperlipidemia and these statistics prove that the increasing patient pool is directly proportional to the market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall lipid disorder treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of obesity and other lifestyle disorders in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market.

Furthermore, higher incidence of familial combined hyperlipidemia, beneficial government initiatives and increase awareness of the treatment are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share. According to Center for Chronic Disease Prevention (CDC), 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol, therefore a growing number of these diseases in the country is anticipated to stimulate the demand in this region.

Competitive Landscape

The lipid disorder treatment market is moderately competitive and consists of major players. Some of the companies which are currently domianting the market Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc., Sun Pharma, Emcure Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Wockhardt Limited.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Prevalence of Several Lifestyle Diseases
    • 4.2.2 Rise in the Smoking and Alcohol Consumption
  • 4.3 Market Restraints
    • 4.3.1 Side effects of the treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Hypercholesterolemia
    • 5.1.2 Dysbetalipoproteinemia
    • 5.1.3 Familial Combined Hyperlipidemia
    • 5.1.4 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Online Pharmacies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer, Inc
    • 6.1.2 Novartis AG
    • 6.1.3 Astrazeneca Plc
    • 6.1.4 Merck & Co. Inc.
    • 6.1.5 Emcure Pharmaceuticals Ltd.
    • 6.1.6 Ranbaxy Laboratories Ltd.
    • 6.1.7 Teva Pharmaceuticals
    • 6.1.8 Mylan Pharmaceuticals, Inc.
    • 6.1.9 Kowa Pharmaceuticals America, Inc.
    • 6.1.10 Glenmark Pharmaceuticals Ltd.
    • 6.1.11 Sun Pharmaceuticals Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS